Seminars & Events
The Chemistry and Biochemistry Department hosts various events scheduled throughout the year, including a weekly seminar series. See the calendar below for information on these events and details about our seminar speakers.
Dr. Deborah Wuttke is a Professor in the Department of Chemistry and Biochemistry at the University of Colorado Boulder. Research in the Wuttke lab is poised at the interface of biochemistry, biophysics and biology. Our lab aims to understand the underlying molecular mechanisms behind important biological processes. Recently, we have focused our efforts on telomere biology, attempting to understand the structural and biochemical basis for the maintenance of the ends of chromosomes. Disruption of telomere maintenance is catastrophic for the cell, and telomere processes are linked to both cancer and aging. We are also studying viral replication in the picornavirus family and the ligand binding properties of the estrogen receptor. A common theme is bringing sophisticated structural and biochemical tools to complex biological systems.
In addition to being a research advisor in the Ph.D. program in Biochemistry, Dr. Wuttke participates in the Biofrontiers Institutes' Interdisciplinary Quantitative Biology (IQ Biology) PhD certificate program, the Molecular Biophysics certificate program, and the Signaling and Cellular Regulation training program. Dr. Wuttke has also been very active in diversity and inclusion efforts at both the student and faculty levels within the University of Colorado.
Dr. Sherri McFarland obtained her PhD in Chemistry at the University of California San Diego (2003) where she focused on the control of excited state dynamics for luminescent chemosensing. Building on this work, she completed a post-doctoral fellowship at Dalhousie University (2005) in ultrafast spectroscopy and inorganic photophysics, using femtosecond laser techniques.
Dr. McFarland continues to expand these core areas of expertise through a multidisciplinary research program aimed at developing new photoactive drugs (in combination with light sources and protocols) as anticancer agents and as antibiotics. Some of the most promising compounds have been licensed to a Toronto company and are undergoing clinical trials to treat non-muscle invasive bladder cancer.
Sherri also co-founded a company that develops natural product-based photoactives, with particular focus on improving oral health. She has raised over $2M in research and development funding and has co-authored more than 80 scientific works.